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Summary 
The singular ability of immunoglobulin genes to hypermutate their variable regions, while 
permitting the generation of high-affinity antibodies against foreign antigens, poses a problem 
in terms of maintenance of immunological self-tolerance. Immunoglobulin gene hypermutation 
driven by a foreign antigen has the potential to generate antibodies that cross-react with self- 
components. Consequently, there must exist a mechanism in the periphery for inactivation of 
mature autoreactive B cell clones. The classical experimental system used to address this problem 
is the induction of tolerance to soluble, deaggregated human IgG. We have analyzed the mechanism 
of induction of tolerance to human IgG using transgenic mice that express a human IgM rheumatoid 
factor (IgM RF) on a large proportion of their B cells. Injection of deaggregated human IgG 
caused a specific deletion of those B cells that express an intact IgM RF on their cell surface. 
The degree of RF B cell deletion was proportional to the reduction in the proliferative response 
of splenocytes to antigen (aggregated human IgG), or to F(ab')2 fragments of anti-human IgM 
antibodies. Control experiments showed that IgG administration had little effect on the numbers 
of mouse Ig-bearing cells or their ability to proliferate to a nonspecific mitogen. Thus, the effects 
of IgG on the human IgM RF B cell are antigen specific and are not due to nonspecific toxic 
effects of the human IgG preparation. These experiments demonstrate that peripheral exposure 
to IgG induces deletion of reactive B cells, without any evidence for anergy,  and differ from 
data obtained by other investigators studying tolerance to soluble protein antigens.  The results 
imply that human Igs have distinct properties as soluble antigens, and that peripheral nonre- 
sponsiveness to IgG may be due to lymphocyte deletion. 
T 
he induction of immunologic nonresponsiveness to sol- 
uble, deaggregated human IgG is one of the classical ex- 
perimental systems for analysis of peripheral tolerance in both 
B and T cells (1). Although data have shown that the number 
of antigen-binding B cells is reduced in the periphery, the 
low frequency of these cells makes it difficult to determine 
whether this reduction is due either to downregulation or 
modulation of surface immunoglobulin, or to lymphocyte 
deletion. Experiments carried out more recently using trans- 
genic mice which express immunoglobulins specific for hen 
egg lysozyme (HEL) 1 (2-5) and for H-2 antigens (6, 7) have 
confirmed that the predominant mechanisms responsible for 
B lymphocyte nonresponsiveness to self antigens are physical 
deletion of self-reactive cells, termed donal deletion, and func- 
tional silencing of self-reactive cells, termed anergy.  It has 
Abbreviation used in this paper: HEL,  hen egg lysozyme. 
been suggested that the degree of immunoglobulin receptor 
cross-linking determines the fate of an autoreactive B cell (4). 
According to this hypothesis, recognition of monomeric or 
soluble antigen induces anergy and recognition of highly mul- 
tivalent membrane bound antigen results in deletion. Con- 
sequently,  the injection of soluble,  heterologous immuno- 
globulins would be expected to lead to B cell inactivation 
by induction of anergy. 
We have previously shown that B cells from transgenic 
mice which express a human IgM rheumatoid factor (RF) 
share many properties with IgM RF-bearing B cells from 
normal individuals (8). They comprise a significant propor- 
tion of the adult B cell population, but secrete only low levels 
of RF into the serum. B cells expressing the RF transgene 
show characteristic  localization to primary follicles and the 
mantle zone regions of secondary follicles in the spleen. Al- 
though serum IgM RF levels are low in these mice, they can 
be substantially  increased by breeding the transgenic mice 
onto the autoimmune prone MRL/Ipr background. 
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human IgG induces deletion oflgM RF B cells in transgenic 
mice. These results lead us to believe either that the proper- 
ties of IgG interacting at high concentrations with B cells 
expressing this IgM RF may distinguish it from other soluble 
antigens that induce anergy in reactive B cells, or that divi- 
sion of antigens into those that induce deletion and those 
that induce anergy may not be as absolute as previously con- 
sidered. 
Materials  and Methods 
Mice.  The initial AB29 IgM RF transgenic line was described 
previously (8). It derived from B6  x  SJL F2 injections and has 
since been maintained by crossbreeding with C57B1/6 mice (The 
Jackson Laboratory, Bar Harbor, ME). Those mice used in the de- 
scribed experiments were aged 6 wk or older, and were derived 
from sixth  generation,  or later, backcrosses to C57B1/6. 
ELISA.  Positive  progeny of transgenic matings were identified 
by measuring the level of human IgM RF in the serum of 4-5-wk- 
old mice. Plates were coated with human IgG (Cappel, Durham, 
NC) at 10/xg/ml, and binding of serial dilutions of mouse serum 
was determined by sequential addition of anti-human IgM-biotin 
(Accurate Chemical & Scientific Corp.,  Westbury, NY), strepta- 
vidin-peroxidase (Kirkegaard & Perry Laboratories, Inc., Gaithers- 
burg, MD) and peroxidase substrate (KPL). Absorbance was mea- 
sured  at  450  nm.  Levels of  expression  were  determined  by 
comparison with a standard curve of binding by purified Les IgM 
RF. 
Tolerance Induction To  Human  IgG.  Mice  were  injected in- 
traperitoneally with 2 mg deaggregated human IgG unless stated 
otherwise.  Initial experiments used pooled human  IgG obtained 
from a commercial source (Cappel). However, the majority of the 
experiments described here used human IgG1 which was purified 
from the serum of a myeloma patient.  Briefly, serum was filtered 
and then purified on a protein A-agarose column (Sigma Chemical 
Co., St. Louis, MO). After extensive  dialysis against PBS and testing 
for levels of endotoxin, the human IgG was considered suitable for 
use. Human IgG was deaggregated by centrifugation at 100,000 g 
for 150 min at 4~  The top 25% of the gradient was carefully 
removed, the Ig concentration  was checked and adjusted with 
pyrogen-free 0.15 M NaC1 to 4 mg/ml. 2-mg aliquots were then 
immediately injected intraperitoneally  into mice. 
Cell Preparation for Fluorescence Activated Cell Sorter Analysis. 
Spleens were removed from AB29 transgenic mice or nontrans- 
genie littermates and gently teased apart in RPIO medium (RPMI 
1640 [Irvine Scientific, Santa Ana, CA] supplemented with peni- 
cillin and streptomycin, glutamine, 2-ME and 10% heat-inactivated 
FCS [Gemini Biolabs, Calabasas, CA]). Peripheral blood was col- 
lected from the mice into heparinized tubes. Before analysis by 
FACS  |  (Becton Dickinson & Co., San Josr, CA), viable white cells 
were isolated using cell separation gradients (Lympholyte M, Ac- 
curate, Westbury, NY). Cells obtained from the interface of these 
gradients were washed with FACS  |  medium (PBS/3%FCS/0.1% 
sodium azide) before use. 
FACS  |  Analysis of Spleen or Peripheral  Blood.  Cell staining was 
carried out as previously  described (8), using the following reagents: 
goat anti-human IgM-FITC (Jackson Immuno Research Labora- 
tories, West Grove, PA); anti-B220-PE (PharMingen, San Diego, 
CA); anti-mouse K-PE (Fisher Scientific  Co., Pittsburgh, PA); goat 
anti-human kappa-biotin (Sigma Chemical Co.); and streptavidin- 
PE (Molecular Probes, Inc., Eugene, OR). Cells were either ana- 
lyzed on a FACScan  |  (Becton Dickinson & Co.) immediately after 
staining or fixed with 1.5% paraformaldehyde for 45 rain on ice. 
Fixed samples were analyzed at a later time. 
B Cell Proliferation Assays.  Spleens  were removed from trans- 
genie mice or nontransgenic littermates. Cells were teased apart, 
washed and resuspended at 2  x  106/ml in RP10 medium. 2  x 
l0  s ceils were added to each well of a round-bottomed 96-well 
plate in a total volume of 100 #1. A further 100/zl of medium was 
then added containing one of a number of antibodies; F(ab')2 frag- 
ments of  affinity-purified,  goat anti-human IgM (Jackson Immuno 
Research Laboratories); aggregated human IgG (Cappel); or LPS 
from Salmonella minnesota (Sigma Chemical  Co.).  Aggregated 
human IgG was prepared by heating a 10-20 mg/ml solution at 
63~  for 1 h followed by cooling on ice for 2 h. All tests were 
performed in triplicate and proliferation was measured at day 3-4 
by the addition of 1/~Ci of [3H]TdR per well. The assay was ter- 
minated 18 h after addition of the [3H]TdR by harvesting plates 
using  a cell automated  harvester (Cambridge Technology, Inc., 
Watertown,  MA). 
Immunohistochemistry.  Tissues  were snap-frozen in optimal cut- 
ting temperature medium (Miles Laboratories,  Inc., Naperville, IL). 
4-/~m sections were prepared from the tissue blocks and stained 
with  affinity-purified goat  anti-human  IgM-biotin  or  affinity- 
purified goat anti-mouse  IgM-biotin (Jackson Immuno Research 
Laboratories) and streptavidin-linked alkaline phosphatase (KPL). 
Briefly, 100/xl of  medium or an optimal dilution of the biotinylated 
reagents was added to each slide and incubated for 30 min at room 
temperature. Slides were then washed with pH 8.0 borate buffered 
saline (BBS), before adding 100/zl of streptavidin-linked alkaline 
phosphatase for a further 30 min. After washing the slides with 
BBS, the bound alkaline phosphatase was detected using a Histo- 
mark Red staining kit (KPL) in which specific  staining is blue and 
the tissue background  is red. 
Results 
Time Course of Deletion of lgM RF B  Cells.  AB29 mice 
were injected intraperitoneally with 2 mg of purified deag- 
gregated human IgG1 myeloma protein. The mice were bled 
periodically and the phenotype of their PBL analyzed over 
time. Data shown in Table 1 express the results in terms of 
the percentage of B cells (B220 +) and human IgM positive 
cells (hlgM,  /~  specific). 
It is apparent that injection of human IgG results in the 
removal of peripheral B cells that express human IgM on their 
cell surface.  Interestingly, the time after injection of human 
IgG, at which levels of IgM positive B cells are no longer 
significantly different (p >0.05) from saline-treated controls 
i.e.,  "~7 wk, is the time at which B cell responsiveness  to 
human IgG returns in.classical HGG (human IgG) tolerance 
as a result of tolerogen catabolism (9). This implies that non- 
responsiveness in this latter system may indeed be due to de- 
letion. 
Effect of Human IgG on the Phenotype  and Functional Ca- 
pacity of the RF B Cell.  The effect of human IgG on splenic 
lymphocytes in terms of their phenotype and functional ca- 
pacity was then analyzed more fully. In the experiments shown 
in Table 2, we analyzed mice 3 wk after injection of deag- 
gregated human IgG. 
Deletion of human IgM-expressing B cells is accompanied 
600  IgG Induced Deletion of RF B Cells Table  1.  Time Course of the Effect of Deaggregated Human  IgG on the Peripheral Blood Phenotype 
B220  hlgM 
Time  hlgG inj.  Saline inj.  hlgG inj.  Saline inj. 
Prebleed  34.5  •  3.8  42.4  +  11.1  18.3  •  1.5  20.8  •  1.7 
Week  1  12.9  •  2.0  32.3  •  2.7  1.5  •  0.3  16.8  +  0.9 
Week 3  15.0  •  1.9  32.4  +  2.0  6.2  •  1.7  18.3  •  1.6 
Week  5  17.4  •  1.5  32.1  _+  1.0  8.5  •  1.0  16.0  _+  0.5 
Week  7  27.1  •  1.5"  32.1  •  2.5  15.8  •  2.3*  19.3  •  1.1 
Mice were bled at various times relative to intraperitoneal injection of either deaggregated human IgG (hlgG inj.) or saline (sal. inj.) as control. 
PBL were then stained for surface expression of either B220 (total B cells) or human IgM and analyzed on the cytofluorograph. Data are expressed 
as percentage of positive cells  _+ SE for groups of three or four mice. Levels of both B cells (B220+)  and hlgM cells are significantly reduced  in 
the hlgG-injected group compared with the saline control from weeks 1-5 (p <0.002).  Values  at week 7: 
* p  =  0.18 for B220; 
r p  =  0.20 for hIgM. 
by a reduction in the proliferative response of splenocytes to 
both  antigen  (aggregated human  IgG)  and to  F(ab')2 frag- 
ments of anti-human  IgM antibodies (Table 2). It is obvious 
that the effect of the deaggregated human  IgG is specific for 
the  human  IgM  RF-expressing  B  cells  and  is  not  due  to 
nonspecific toxicity of the preparation. Cells expressing mouse 
immunoglobulin  are unchanged  in number.  A  similar lack 
of significant effect on the levels of mouse kappa bearing cells 
was obtained in six out of seven experiments.  IgG adminis- 
tration does not alter the proliferation of splenocytes in re- 
sponse  to  LPS. 
The antigen specificity of the deletion is confirmed when 
splenocytes are costained for both human IgM (# chain specific) 
and human kappa (Table 3). Double staining B  cells are pref- 
Table  2.  Effect of Deaggregated Human IgG on Phenotype and Functional Properties of Spleen Cells 
Phenotype  Proliferation in response to: 
Transgenic  Tolerization  B220  hlgM  mkappa  Anti-hlgM  Agg.  hlgG  LPS 
% 
Saline  51.7  22.6  21.8  31,954  15,577  18,047 
+  5.1  •  1.5  •  4.3  +  2,753  _+  894  _+  2,216 
hlgG  39.4  6.7*  23.2*  7,014s  1,14611  17,235￿82 
+  3.9  _+  2.2  •  1.3  +  1,965  _+  557  •  1,444 
Saline  64.2  0.5  57.6  843  0  40,974 
•  3.8  _  0.1  _+  2.8  +  47  +  934 
hlgG  63.4  0.3  57.9  574  0  47,837 
_+  3.5  _+  0.1  -+  2.6  +  306  •  3,749 
AB29 transgenic mice ( + ) or nontransgenic littermates ( -  ) were killed 3 wk after intraperitoneal injection of either deaggregated human IgG (hlgG) 
or saline as control. Data are expressed as the mean  _+ SE of groups of three mice. Spleen cells were prepared and then stained for phenotypic analysis 
on the cytofluorograph (left three columns) or for their proliferative response to a variety of stimuli (right three columns). The phenotypes are ex- 
pressed as the percentages  of cells within a lymphoid scatter distribution (defined by forward versus  side scatter)  that stain for either surface B220 
(B cells), human IgM (# chain specific, hlgM), or mouse kappa (mkappa). The proliferation data are expressed as counts per minute measured on 
day 3-4 after stimulation of 2  x  10 s splenocytes with F(ab')2 fragments of goat anti-human IgM antibodies at 10 #g/ml; heat aggregated human 
IgG (agg. hlgG) at 200 ng/ml; or LPS at 10 #g/ml. Background proliferation in the presence of medium alone has been substracted from all values. 
p  =  0.0004. 
sp  ~  0.002. 
Cp  =  0.77. 
II p  =  0.0002. 
￿82  =  0.77. 
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Phenotype (total lymphocytes)  Phenotype (total hlg* lymphocytes) 
Tolerization  B220  hK  hx plus hlgM  hlgM  hK  h~ plus hlgM  hlgM 
Saline  29.1  0.6  14.1  1.8  4  86  11 
+  1.5  •  0.2  _+  1.1  •  0.5 
Human IgG  12.8  0.8  1.2"  1.0  27  40  33 
_+ 1.2  •  0.5  •  0.2  •  0.1 
Transgenic mice were bled 3 wk after intraperitoneal  injection of either human IgG (n  =  9) or saline (n  ffi  7) as control.  Peripheral blood cells were 
then stained for phenotypic analysis on the cytofluorograph.  Data in the left four columns are expressed as the percentage of cells within a lymphoid 
scatter distribution (defined by forward versus side scatter) that stain for either surface B220 (B cells), human kappa light chain (hx) alone, human 
kappa plus human IgM (# chain specific, hlgM), or human IgM alone. Data in the right three columns show these values as a percentage of the 
total cells that express human Ig (either kappa or #). Background staining of the anti-human Ig reagents with nontransgenic lymphocytes has been 
deducted from the percentages shown. 
*/,  =  0.0001. 
erentially deleted, and residual B cells which express either 
human kappa or human IgM, presumably in association with 
mouse immunoglobulin, are relatively spared. Such data are 
also shown in Fig. 1 as a double-color FACS  |  profile. It should 
be noted that in m15% of cases (6/38 mice in seven separate 
experiments), deaggregated human IgG fails to induce a sub- 
stantial  reduction (>50%)  in  the  levels of human IgM- 
expressing ceils. It has previously been shown that the pres- 
ence of LPS prevents induction of tolerance to human IgG 
(10). It is possible that the few mice which did not delete 
were suffering from an acute bacterial infection at the time 
of human IgG injection which would have prevented the in- 
duction of tolerance. Data from such mice are not included 
in the results shown, although their inclusion would still have 
resulted in a significant reduction (p <0.05)  in the number 
of B cells expressing both surface human IgM and K. 
The reduction in total B cell levels made it unlikely that 
human IgG was merely downregulating human IgM RF from 
the B cell surface. Immunohistologic analysis of treated mice 
confirms this conclusion (Fig. 2). Spleens were removed from 
mice 3 wk after injection of either saline (A and B) or human 
IgG (C and D), sectioned, and stained for the presence of 
mouse IgM (# chain specific, A and C), or human IgM (# 
chain specific, B and D). IgM RF B cells in the AB29 IgM 
RF transgenic mice characteristically localize to primary fol- 
licles and the mantle zones of secondary follicles in the white 
pulp (8). This is the area in which small resting B cells are 
normally located, and is similar to the localization pattern 
of RF B cells in normal humans (11). In addition,  scattered 
positive cells are located in the red pulp, a region through 
which all blood cells percolate. Presumably, some of these 
latter cells include the plasma cells that secrete the low levels 
of IgM RF detected in the serum. Treatment of AB29 mice 
results in preferential loss of cells from the primary follicles 
and mantle zones of secondary foUides and relative sparing 
of cells located within the red pulp. This is not unexpected 
as the existing plasma cells lack surface immunoglobulin and 
consequently cannot be signaled in either a positive or nega- 
tive manner by antigen.  Staining for mouse IgM confirms 
that treatment does not destroy the follicles or otherwise 
disrupt the normal architecture of the spleen. These results 













TG+: deaggregated human IgG 
Human IgM 
IgG Induced Deletion of RF B Cells 
Figure  I.  FACS*  analysis of PBL from transgertic (TG +) 
mice. TG  + mice were bled 3 wk after intraperitoneal in- 
jection of tither saline  as control (/eft) or deaggregated human 
IgG (right). PBL were then stained for surface human kappa 
(y-ax/s) or surface human IgM (tz, x-ax/s). Figure 2.  Immunohistochemical 
analysis  of  spleen  sections  from 
AB29 mice (TG +) injected with ei- 
ther saline (control) or de.aggregated 
human  IgG.  TG +  spleens  were 
harvested 3 wk after intraperitoneal 
injection of saline (A and B) or 2 
mg deaggregated human  IgG (C 
and D). Sections were stained for the 
presence of mouse IgM (/~ specific, 
A and C) or human IgM (/~ specific, 
B and D). Each panel is divided to 
show both low power views (x 100) 
and high power views (x400) of the 
same section. 
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ulated. In addition, they suggest that soluble human IgG does 
not cause B cell loss through maturation to the plasma cell 
level, because IgM R.F-expressing cells do not appear to in- 
crease in the red pulp after the host is treated with soluble IgG. 
Discussion 
Somatic hypermutation of Ig genes makes possible the se- 
lection and expansion of high affinity antibodies to foreign 
antigens. However, a consequence of this hypermutation is 
that is that it imposes a necessity for the immune system to 
not only maintain central tolerance to self-components but 
also to induce peripheral tolerance in mature B cells that have 
left the bone marrow and, because of  diversification, may have 
acquired reactivity to self. Such a mechanism of peripheral 
tolerance may be essential for the prevention of autoimmune 
diseases. 
Immunologic unresponsiveness in the adult mouse after 
injection of soluble, deaggregated human IgG is the most 
thoroughly studied system of acquired peripheral tolerance 
(1, 9, 12-14). The doses of antigen and kinetics of induction 
in both the T and B cell populations  have been fully docu- 
mented. After a single dose of tolerogen, nonresponsiveness 
is long-lasting in the T cell compartment but of shorter du- 
ration in the B cell compartment. However, the exact mech- 
anism of B cell inactivation is not known because of the low 
frequency of human IgG-specific B cells under normal cir- 
cumstances. To overcome this barrier, we have studied AB29 
transgenic  mice that express a human IgM antibody with 
specificity for human IgG (a human IgM RF). The AB29 
transgenic mice express the Les human IgM RF on a large 
proportion (mean =  70%, range =  46-90%) of their ma- 
ture B cells, but similarly to normal humans,  show charac- 
teristically low levels of IgM RF in the serum (mean level 
in AB29 mice --  12.9 #g/ml; 8). The transgenic heavy and 
light chain Ig genes were isolated from the DNA of a chronic 
lymphocytic leukemia patient who had associated systemic 
vasculitis (15-17). The Vk derives from Vk328, a conserved 
Vk3 subgroup gene that often encodes light chains of human 
autoantibodies. The Vh gene most likely derives from Vh4.21 
(17-19). A number of point mutations result in the produc- 
tion of a higher affinity RF than would normally be pro- 
duced by the germline genes themselves. 
Injection of soluble, deaggregated  human IgG results in 
deletion of IgM RF-bearing B cells from the periphery of 
AB29 transgenic mice. Lack of IgM RF B cells was not due 
to downregulation or internalization  of surface Ig because 
there was a similar reduction in the total number of B cells 
in both the spleen and blood. Neither could it be explained 
as a loss of B220-expressing cells due to maturation of IgM 
RF B cells to a plasma cell stage, as staining of treated spleen 
sections showed a significant reduction of IgM RF B cells 
in the primary follicles and mantle zones of secondary fol- 
licles, and there was no indication  of a greater  number of 
plasma cells in the red pulp. The antigen specificity of the 
deletion was confirmed by a preferential reduction in B cells 
which expressed both human IgM (#) and kappa and so had 
the potential for binding human IgG, and a relative sparing 
of those B cells that expressed  either human IgM (/z) or kappa 
alone, presumably in association with mouse immunoglob- 
ulin. Nonspecific toxicity of the human IgG preparation was 
also ruled out by a generally  insignificant  effect  on the numbers 
of mouse K-bearing B cells. Moreover, the IgG administra- 
tion did not reduce responsiveness to the nonspecific B cell 
mitogen LPS. 
The effects of deaggregated human IgG in transgenic mice 
show a number of striking similarities to previously published 
studies of human IgG (HGG) tolerance (1, 9, 12-14). In both 
systems, induction of tolerance is dose dependent. Thus, 0.1, 
0.5, and 2.5 mg of deaggregated human IgG induced 9, 56, 
and 70% B cell unresponsiveness,  respectively,  in normal mice 
(9), whereas in the AB29 mice, injection of 0.25 and 2.5 mg 
resulted in deletion of 39 and 90% of human IgM (/z) posi- 
tive B cells, respectively (data not shown).  In normal mice, 
B cell tolerance was lost 49 d after injection of tolerogen. 
In AB29 mice, levels of human IgM (/z)-bearing B cells were 
restored to normal by 49 d.  In both cases it is likely that 
the circulating concentrations of  human IgG drop with time 
(20), eventually enabling B cells which have newly emerged 
from the bone marrow to survive. 
Our finding of B cell deletion in mice exposed to deag- 
gregated human IgG contrasts with earlier data obtained in 
transgenic models of peripheral tolerance in which soluble 
antigens induced anergy, whereas multimeric or cell surface 
antigens induced deletion (2-4, 6, 7, 21, 22). However, human 
IgG has distinct immunological properties that distinguish 
it from other antigens such as an ability to bind to Fc receptors 
and fix complement, besides interacting with IgM RF. Cross- 
linking of surface Ig by either antigen or F(ab')2 fragments 
of anti-Ig antibodies usuaUy results in B cell activation. These 
activation signals are downregulated if surface Ig is cocross- 
linked with FcylI receptors (23-31). Although the high affinity 
binding site for the Les RF is in the Fc portion of human 
IgG (Carson, D. A., unpublished results), the antigen-anti- 
body complex is very poorly soluble. Thus, it is possible that 
a portion of the deaggregated human IgG which is injected 
into the mice aggregates at the B cell surface, aided either 
by the low levels of human IgM RF present in the circula- 
tion or by low affinity,  polyspecific  mouse IgM of a type similar 
to that naturally  found in humans.  The presence at the B 
cell surface of small aggregates of human IgG/IgM RF could 
potentially lead to negative signaling through simultaneous 
binding to surface Ig and Fc receptors.  It is interesting  in 
this regard that classically the most effective antigens for in- 
duction of tolerance have been gamma globulins (32). In ad- 
dition, it was recently reported (33) that anergic B cells have 
a reduced life span in the periphery, indicating that a distinc- 
tion between B cell anergy and deletion may not be absolute. 
Instead, the effects of antigen on lymphocyte numbers may 
depend on the kinetics of cell turnover after antigen exposure, 
compared with the rate of cell generation. 
Results from other studies (34) analyzing the effect of IgG 
on central tolerance of mouse IgM RF-expressing B cells show 
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may even have been expanded by antigen. Whereas it is not 
altogether clear why these results differ from our finding of 
peripheral tolerance by deletion, it is likely that the amount 
of antigen present in these mice ('~50 #g/ml of mouse IgG2a) 
is probably less than the peak achieved in AB29 mice injected 
intraperitoneally with 2 mg of deaggregated human IgG. In 
addition, this level of IgG is also less than the concentration 
of IgG present in the serum of normal individuals. 
Lymphocytes bearing cell surface IgM RF  constitute a 
significant proportion of adult B cells in humans (35). Obvi- 
ously then, some IgM RF B cells which react with human 
IgG remain in normal individuals in spite of the presence 
of antigen. This is potentially due to differences in affinity 
of the IgM RFs. Germline encoded IgM RFs are generally 
of low affinity and frequently polyspecific (10 -4 to 10 -s M; 
36). The Les IgM RF is specific for human IgG and of higher 
avidity because of a number of point mutations (14-16,  and 
our unpublished results). Secretion of this autoantibody led 
to immune complex formation and vasculitis  in the patient 
from which these genes were derived. 
Higher affinity R.Fs may arise naturally as a consequence 
of somatic hypermutation and diversification of immunoglob- 
ulin genes during normal antigen-driven immune responses. 
We and others (8,  37)  have previously shown that one of 
the physiological functions of normal IgM RF B cells may 
be to present antigen, in the form of immune complexes with 
human IgG, to antigen-specific T  cells. Therefore, while it 
is unlikely that IgG-specific T cells would escape central toleri- 
zation, T cells reactive to foreign antigens also have the poten- 
tial for stimulating the RF B cell.  Recent data with anti- 
HEL transgenic mice indicate that anergic B cells maintain 
their nonresponsive state in the presence of helper T cells and 
soluble antigen.  However,  use of HEL  in  a more potent 
membrane-bound form in the presence of T  cell help (38), 
or transfer of anergic B cells together with T  helper cells 
and HEL  emulsified in  adjuvant to  irradiated third party 
recipients (39) leads to antibody production by the previously 
anergic B cells. RF-expressing B cells must be exposed inter- 
mittently to highly cross-linked human IgG in the form of 
an immune complex, together with T  cells reactive to the 
antigen component of the immune complex. Under these 
circumstances, deletion may be essential, otherwise higher 
affinity RF B cells retained in an anergic state might reactive 
and trigger autoimmunity. 
We postulate that RF B cells which express low affinity 
IgM RFs fail to be inactivated or stimulated by soluble IgG. 
They may however, serve as excellent APCs for any antigen 
present in the form of an immune complex with IgG, resulting 
in an expansion of responsive T  cells early in a secondary 
immune response. This would account for the increase in 
RF precursor B cells which normally accompanies a secondary 
immune response (40).  IgM RFs in humans have been con- 
sidered unusual in their apparent lack of somatic mutation 
and class switching. We would suggest that IgM RFs may 
indeed have the ability to undergo affinity maturation. In 
addition, the normal process of somatic mutation in other 
antibody genes may generate antibodies that cross-react with 
IgG. The presence of immune complexes and antigen-specific 
T  cells would then lead to the activation of both low and 
high affinity RFs. However, after clearance of antigen, B cells 
expressing higher affinity R.Fs would be deleted by high levels 
of circulating soluble IgG in the absence of T cell help. Under 
circumstances where such peripheral deletion is defective, T 
cells reactive with any antigen capable of forming an immune 
complex with human IgG, would be able to stimulate and 
maintain production of high affinity RFs. This may be the 
situation that we observe in diseases such as rheumatoid ar- 
thritis and systemic lupus erythematosus. 
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